Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Early Feasibility Study of the ReHAB System (ReHAB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03898804
Recruitment Status : Not yet recruiting
First Posted : April 2, 2019
Last Update Posted : April 2, 2019
Sponsor:
Information provided by (Responsible Party):
Jonathan Miller, MD, University Hospitals Cleveland Medical Center

Brief Summary:

The purpose of this research study is to examine the feasibility of a system that involves implanting small electrodes in the parts of the brain that control movement and sensation, and combining that with electrodes in the upper arm and shoulder to activate paralyzed muscles of the arm and hand. This system is intended for people with extensive paralysis in their arms. The small electrodes in the brain will be used to attempt to measure intended movements, and the muscles in the arm and hand will be stimulated to attempt to follow those intentions.

The study is a prospective, non-randomized, open-label, exploratory safety/feasibility trial of up to 12 subjects. The Primary Endpoint will be evaluation over the first 13 months after implantation, after which the subjects will have the option of removal of the device or continued participation in a long-term study.


Condition or disease Intervention/treatment Phase
Tetraplegia Device: BCI and FES Not Applicable

Detailed Description:

The overall purpose of this trial is to advance development of a novel technological approach to allow individuals with tetraplegia to interact with their environment using their own paralyzed limbs by combining recording of brain activity, brain stimulation to provide sensory feedback, and stimulation of the paralyzed extremities based on neural recordings.

Device Name:

Reconnecting the Hand and Arm to the Brain (ReHAB) System

Intended Use The proposed device is intended to allow greater functional independence for individuals who are paralyzed due to disease or injury. The purpose of this trial is to advance development of a novel technological approach to allow individuals with tetraplegia to interact with their environment using their own paralyzed limbs by combining recording of brain activity, brain stimulation to provide sensory feedback, and stimulation of the paralyzed extremities based on neural recordings.

The target population are individuals with high tetraplegia, defined as less than antigravity weakness of both upper extremities and both lower extremities as a result of an identified and static (stable for at least 3 months) injury or disease affecting upper motor neurons process that prevents motor neural activity from activating muscles below the neck to perform functional activities. Injuries and diseases that lead to this clinical condition include spinal cord injury, and stroke.

Objective(s):

The primary objective of this study is to evaluate the safety, tolerability, and potential efficacy of an approach combining multiple intracortical brain recording/stimulating microarrays with direct peripheral nerve and muscle stimulation for restoration of arm and hand movement in people with high tetraplegia.

Secondary objectives include validation of the combined platform described above as a clinical device to allow paralyzed individuals to have a more meaningful interaction with their environment as assessed by ability to perform brain-controlled reaching and grasping tasks that ultimately might allow for greater functional independence.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Intervention Model Description: The study is a prospective, non-randomized, open-label, exploratory safety/feasibility trial of up to 12 subjects. The Primary Endpoint will be evaluation over the first 13 months after implantation, after which the subjects will have the option of removal of the device or continued participation in a long-term study for an additional 5 years, for a total of up to 73 months.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Early Feasibility Study to Assess the Effects of the "Reconnecting the Hand and Arm to the Brain (ReHAB)" System
Estimated Study Start Date : May 1, 2019
Estimated Primary Completion Date : March 1, 2024
Estimated Study Completion Date : March 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rehabilitation

Arm Intervention/treatment
Experimental: BCI and FES
Surgical implantation of the device and testing for 13 months with an optional 5 year extension study.
Device: BCI and FES
The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.




Primary Outcome Measures :
  1. Incidence of treatment-related adverse events [ Time Frame: 13 months ]
    Successful implantation of brain and extremity recording/stimulating electrodes for 1 year without explantation or device-related serious adverse events.


Secondary Outcome Measures :
  1. Success rate of target acquisition of a cursor on a computer screen controlled by neural signals, using a standard center-out-center random target display. [ Time Frame: 13 months ]
    The participant will control the position of a cursor on a monitor using the recorded neural signals and attempt to move the cursor to the target.

  2. Change in number of tasks performed as measured by the ADL Abilities Test. [ Time Frame: 13 months ]
    The participant will control the stimulated movement of their arm and hand using the recorded neural signals. The participant will demonstrate the ability to perform some of the activities of daily living (ADLs) that are part of the ADL Abilities Test.

  3. Change in number of objects successfully grasped and moved during a timed session, as measured by the Grasp Release Test. [ Time Frame: 13 months ]
    The participant will control the stimulated movement of their arm and hand using the recorded neural signals. The participant will demonstrate the ability to grasp and move a series of objects that are part of the Grasp Release Test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 22 and 65 years of age.
  2. Tetraplegia due to a static identified disease process (spinal cord injury or stroke) that prevents functional activity of the upper extremity.
  3. Onset of tetraplegia at least 12 months prior to enrollment, with stability of weakness for at least 3 months.
  4. Must have sufficiently intact cortical motor structures and stable medical prognoses to be able to perform the BCI control tasks for at least one year. .
  5. Ability to speak understandably or, if unable to speak understandably, a reliable means of yes/no communication.
  6. Life expectancy greater than 13 months.
  7. Chronic care environment within a three-hour drive of the study site or the ability to temporarily relocate to a residence within a three-hour drive of the study site.
  8. Willingness to remain available (geographically stable) for at least 13 months after enrollment, including maintenance of the evaluation schedule, frequent visits to the Investigator's office, and visits of Sponsor personnel to the subject's chronic care environment.
  9. Willingness to allow videotape recordings to be made of the surgical procedure (for training purposes) and portions of the Feasibility Evaluations.
  10. A stable psychosocial support system.
  11. Scalp devoid of any lesions or skin breakdown precluding surgery.
  12. Ability to provide voluntarily informed consent in accordance with Site institutional policies and willingness to release of Personal Health Information from the date of the injury or disease onset through the completion of the clinical Study.
  13. Availability of caregivers capable of providing the necessary daily care of the subject's skin and electrode externalization sites.

Exclusion Criteria:

  1. Presence of an implanted stimulator such as a pacemaker, spinal cord stimulator, cochlear implant, deep brain stimulator, vagus nerve stimulator, or defibrillator. (Implanted intrathecal pumps for pain or spasticity, cough implants, or diaphragmatic pacers are not excluded.)
  2. Any active infection(s) or unexplained fever.
  3. Active cancer within the one year prior to enrollment (other than adequately treated basal or squamous cell skin cancer).
  4. Uncontrolled insulin-dependent diabetes mellitus.
  5. Hydrocephalus requiring diversion of cerebrospinal fluid.
  6. Autonomic dysreflexia within three months prior to enrollment that required urgent evaluation and pharmacologic intervention prescribed by a physician.
  7. Seizure within 3 months prior to enrollment.
  8. Any medical condition expected to require routine MRI imaging or subjects with contraindication(s) to MRI.
  9. History of osteomyelitis or skin disorder that causes excessive skin sloughing, lesions or breakdown of the scalp.
  10. Chronic use of medications such as sedatives that may significantly retard motor coordination and cognitive ability.
  11. Chronic use of anticoagulant medications. (Subjects receiving prophylactic anticoagulation solely for the prevention of deep venous thrombosis are not excluded, but must be able to have their prophylactic anticoagulation suspended temporarily for the surgical procedure and immediate post-operative period.)
  12. Chronic use of steroids or immunosuppressant therapy.
  13. Active treatment for another serious medical, neurological or psychiatric disease or disorder that could seriously affect the subject's ability to undergo surgical implantation of the electrodes or participate in the testing sessions.
  14. Pregnant, lactating, or of childbearing age and not using adequate birth control.
  15. Active consumption of more than 1 alcoholic beverage per day.
  16. Suicide attempt within 12 months prior to enrollment.
  17. History of myocardial infarction or unstable cardiac arrhythmia.
  18. Enrollment in any other investigational study that may interfere with the time commitments required of this study.
  19. Subjects who are immunocompromised.
  20. Subjects who require ongoing diathermy or ultrasound treatments.
  21. Subjects with severe upper extremity joint contractures or Ashworth spasticity scores of 4 that would limit functional movements.
  22. Subjects who have contraindication(s) to CT.
  23. Subjects who are ventilator dependent. Subjects who are sometimes ventilator-assisted (for example, while sleeping) are not excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03898804


Contacts
Layout table for location contacts
Contact: Jonathan Miller (216)844-3470 jonathan.miller@uhhospitals.org

Locations
Layout table for location information
United States, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
Jonathan Miller, MD

Layout table for additonal information
Responsible Party: Jonathan Miller, MD, George R. and Constance P. Lincoln Professor and Vice Chair of Neurosurgery, University Hospitals Cleveland Medical Center
ClinicalTrials.gov Identifier: NCT03898804     History of Changes
Other Study ID Numbers: ReHAB
First Posted: April 2, 2019    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Quadriplegia
Paralysis
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms